Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.
7don MSN
Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...
A study reveals racial and ethnic disparities in access to Novo Nordisk's diabetes and weight loss drugs among U.S. military veterans. Black, Asian, and Native American patients are less likely to ...
7don MSN
Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...
Novo Nordisk, the maker of Ozempic, reported that compounded versions of semaglutide, the main ingredient in Ozempic and ...
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback